Clinical Trials

REGEN-COV Phase 3 Trial Improves Survival in Patients Hospitalized with Severe COVID-19

June 17, 2021

A Phase 3 RECOVERY trial in the UK found that Regeneron’s REGEN-COV antibody treatment reduced the risk of death by 20% in patients who had not mounted their own immune response against COVID-19. In addition, among patients without their own immune response, the median duration of hospital stay was 4 days shorter in the REGEN-COV group, and there was a greater proportion of patients discharged by 28 days. Research has also shown that the treatment remains effective against the main variants of COVID-19 in the United States. 

Read More »

Treating MIS-C with Phase 3 Celiac Drug

June 15, 2021

Even after a COVID-19 infection has passed, SARS-CoV-2 particles may linger in the gut and make their way into the bloodstream. This often triggers a cytokine storm and hyper-inflammatory response (MIS-C) within multiple areas of the body. These include the heart, lungs, kidneys, brain, and GI organs. 

Read More »

The NIH Begins Trial on Mixing COVID Vaccine Boosters

June 2, 2021

A trial funded by the NIH has entered Phase 1/2 testing to study COVID-19 vaccine boosters from different manufacturers on fully vaccinated adults. While it has not been determined whether boosters will be necessary, Dr. Fauci has stated that “we need to prepare for the possibility… to counter waning immunity and to keep pace with an evolving virus”

Read More »

Research Developments on the World’s Prominent COVID-19 Vaccines

May 19, 2021

Researchers around the world are creating and testing close to 100 vaccines in an effort to combat the novel coronavirus. The following Vaccine Comparison Chart provides a breakdown of leading vaccines that have shown promise through pre-clinical data, completed Phase 1/2/3 clinical trials, and have been authorized for emergency use.

Read More »
1 … 3 4 5 6 7 … 10

Browse By Topic